Radioimmunotherapy Platform Target Prioritization in Oncology

A biopharma company needed to conduct a robust landscape assessment and prioritize potential protein targets for a novel radioimmunotherapy (RIT) platform in oncology.

Our team began developing a target database and defining key filtering criteria.  We assessed key datasets covering molecular biology, cancer epidemiology, and oncology drug development to derive a long list of ~1,200 targets. By collaboratively identifying and applying key criteria, we were able to identify the ~45 highest potential targets. Next, we scored the short-listed targets based on a range of scientific and commercial considerations. For each target, we developed a 1-page overview to support decision-making.  Our assessments on the targets were validated via extensive interviews with experts in the relevant fields. Finally, we further reduced the list to 17 targets, categorizing and prioritizing them for client decision-makers.

The client team was provided with a shortlisted and prioritized target list that defines a tumor franchise and development wave strategy aligned to long-term corporate objectives for radioimmunotherapy platform development.